Profile data is unavailable for this security.
About the company
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-11.74m
- Incorporated2012
- Employees5.00
- LocationIntensity Therapeutics Inc1 Enterprise Drive, Suite 430SHELTON 06484United StatesUSA
- Phone+1 (203) 221-7381
- Fax+1 (302) 636-5454
- Websitehttps://www.intensitytherapeutics.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vyome Holdings Inc | 4.19m | -11.35m | 14.62m | 17.00 | -- | 5.69 | -- | 3.49 | -182.98 | -182.98 | 5.45 | 0.4553 | 0.6626 | -- | 6.14 | 246,742.90 | -181.86 | -143.74 | -557.79 | -202.53 | 62.39 | 61.09 | -274.45 | -325.23 | -- | -- | 0.00 | -- | -7.74 | 19.53 | 37.38 | -- | -- | -- |
| Iterum Therapeutics PLC | 390.00k | -26.96m | 14.64m | 9.00 | -- | -- | -- | 37.55 | -0.7488 | -0.7488 | 0.0107 | -0.1507 | 0.0161 | -- | 0.9512 | 43,333.33 | -111.35 | -99.44 | -231.48 | -169.64 | 94.87 | -- | -6,913.08 | -- | 1.96 | -3.43 | 1.28 | -- | -- | -- | 35.44 | -- | -39.16 | -- |
| Curis Inc | 11.65m | -36.56m | 14.87m | 33.00 | -- | -- | -- | 1.28 | -3.68 | -3.68 | 1.05 | -1.15 | 0.3323 | -- | 3.75 | 353,030.30 | -104.28 | -37.70 | -259.56 | -42.63 | 99.47 | 96.89 | -313.79 | -423.79 | -- | -- | -- | -- | 8.83 | 1.75 | 8.49 | -- | -- | -- |
| NuCana PLC (ADR) | 0.00 | -37.50m | 15.18m | 20.00 | -- | 0.4296 | -- | -- | -7,200.04 | -7,200.04 | 0.00 | 4.93 | 0.00 | -- | -- | 0.00 | -106.16 | -47.75 | -180.13 | -58.87 | -- | -- | -- | -- | -- | -1.59 | 0.0052 | -- | -- | -- | 31.25 | -- | -25.32 | -- |
| Traws Pharma Inc | 2.85m | 93.35m | 15.34m | 7.00 | 0.068 | 3.01 | -- | 5.39 | 28.24 | 28.24 | 0.4566 | 0.6373 | 0.2662 | -- | 1.38 | 406,571.40 | -124.51 | -151.85 | -517.46 | -207.35 | -- | -- | -467.64 | -21,652.42 | -- | -- | 0.00 | -- | 0.00 | -36.47 | -188.55 | -- | -- | -- |
| P3 Health Partners Inc | 1.44bn | -131.05m | 15.42m | 360.00 | -- | -- | -- | 0.0107 | -40.18 | -40.18 | 442.85 | -5.72 | 1.91 | -- | 14.07 | 4,013,756.00 | -37.78 | -49.89 | -113.11 | -253.77 | -4.05 | -1.15 | -19.83 | -46.73 | -- | -5.36 | 0.9304 | -- | 18.48 | 59.38 | -135.14 | -- | -- | -- |
| Apimeds Pharmaceuticals US Inc | 0.00 | -5.16m | 15.47m | 2.00 | -- | 1.90 | -- | -- | -0.4762 | -0.4762 | 0.00 | 0.6489 | 0.00 | -- | -- | 0.00 | -111.07 | -- | -138.71 | -- | -- | -- | -- | -- | -- | -162.30 | 0.0577 | -- | -- | -- | -78.73 | -- | -- | -- |
| Intensity Therapeutics Inc | 0.00 | -11.74m | 15.85m | 5.00 | -- | 1.70 | -- | -- | -0.638 | -0.638 | 0.00 | 0.1472 | 0.00 | -- | -- | 0.00 | -158.62 | -117.05 | -230.00 | -201.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.14 | -- | -- | -- |
| Klotho Neurosciences Inc | 0.00 | -11.29m | 16.24m | 3.00 | -- | 1.57 | -- | -- | -0.3264 | -0.3264 | 0.00 | 0.1411 | 0.00 | -- | -- | 0.00 | -180.10 | -- | -197.00 | -- | -- | -- | -- | -- | -- | -1.90 | 0.00 | -- | -- | -- | -556.89 | -- | -- | -- |
| Pasithea Therapeutics Corp | 0.00 | -13.49m | 16.40m | 4.00 | -- | 0.433 | -- | -- | -5.21 | -5.21 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -83.64 | -- | -89.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.34 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -18.50m | 16.70m | 13.00 | -- | 96.91 | -- | -- | -0.4809 | -0.4809 | 0.00 | 0.0026 | 0.00 | -- | -- | 0.00 | -192.59 | -- | -636.43 | -- | -- | -- | -- | -- | -- | -27.09 | 0.9734 | -- | -- | -- | 41.44 | -- | -- | -- |
| LeonaBio Inc | 0.00 | -37.72m | 17.12m | 26.00 | -- | 0.639 | -- | -- | -9.68 | -9.68 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -64.88 | -36.31 | -87.99 | -38.92 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 17.62 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -37.43m | 17.12m | 23.00 | -- | 0.2047 | -- | -- | -3.84 | -3.84 | 0.00 | 3.74 | 0.00 | -- | -- | 0.00 | -32.10 | -29.86 | -52.00 | -35.19 | -- | -- | -- | -- | 0.1257 | -244.30 | 0.0127 | -- | -- | -- | 6.85 | -- | 400.55 | -- |
| Linike Medical Group Ltd | 0.00 | -306.90k | 17.16m | -- | -- | -- | -- | -- | -0.1102 | -0.1102 | 0.00 | -0.153 | 0.00 | -- | -- | -- | -278.62 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -651.26 | -- | -- | -- |
| Lunai Bioworks Inc | 0.00 | -130.98m | 17.21m | 29.00 | -- | -- | -- | -- | -7.51 | -7.51 | 0.00 | -0.5626 | 0.00 | -- | -- | 0.00 | -203.39 | -75.79 | -304.47 | -85.18 | -- | -- | -- | -- | -- | -28.85 | -- | -- | -- | -- | -101.31 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Intensity Therapeutics Inc's reporting currency: US Dollar USD
5.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Sapient Capital LLCas of 31 Dec 2025 | 650.15k | 1.08% |
| Rothschild Wealth LLCas of 31 Dec 2025 | 495.91k | 0.83% |
| Geode Capital Management LLCas of 31 Dec 2025 | 460.25k | 0.77% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 421.03k | 0.70% |
| Mesirow Financial Investment Management, Inc.as of 31 Dec 2025 | 251.00k | 0.42% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 228.05k | 0.38% |
| Legacy Advisors LLCas of 31 Dec 2025 | 153.45k | 0.26% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 136.20k | 0.23% |
| Brown Advisory LLCas of 31 Dec 2025 | 130.00k | 0.22% |
| Stonebridge Financial Group LLC /PA/as of 31 Dec 2025 | 77.38k | 0.13% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
